This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining Kodiak Sciences Bi-Specific Clinical Pipeline for Non-Infectious Uveitis and Geographic Atrophy

Ticker(s): KOD, ALPMF, APLS, ABBV

Who's the expert?

Institution: Iowa Retina Consultants

  • Board Certified Ophthalmologist with Iowa Retina Consultants.
  • Currently manages 1000 patients with Wet AMD and 500 patients for DME.
  • Previously served as President of the Iowa Academy of Ophthalmology and has published articles in a variety of peer-reviewed medical journals.

Interview Questions
Q1.

Roughly how many patients with GA and Non-Infectious Uveitis do you currently manage?

Added By: ben_admin
Q2.

What is the standard of care for GA and NIU?

Added By: ben_admin
Q3.

What is your high level opinion on the data to date on KSI-102?

Added By: ben_admin
Q4.

Do you have an opinion on a Bi-Specific approach targeting both Complement Activation and Cytokines in treating GA and NIU?

Added By: ben_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.